Teva Pharmaceutical (Israel) Buy Hold or Sell Recommendation

TEVA -- Israel Stock  

ILS 4,250  46.00  1.09%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Teva Pharmaceutical Industries Limited is 'Cautious Hold'. Macroaxis provides Teva Pharmaceutical buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TEVA positions. The advice algorithm takes into account all of Teva Pharmaceutical available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from TEVA buy-and-hold prospective. Also please take a look at Teva Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Execute Advice
Sell Teva PharmaceuticalBuy Teva Pharmaceutical
Cautious Hold


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon Teva Pharmaceutical Industries Limited has a mean deviation of 2.03, semi deviation of 0.0, standard deviation of 3.11, variance of 9.69, downside variance of 0.0 and semi variance of 0.0
Macroaxis provides recommendation on Teva Pharmaceutical to complement and cross-verify current analyst consensus on Teva Pharmaceutical Industries Limited. Our buy or sell recommendation engine determines the firm potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Teva Pharmaceutical is not overpriced, please validate all Teva Pharmaceutical fundamentals including its Cash and Equivalents, Total Debt and the relationship between Net Income and Cash per Share .

Teva Pharmaceutical Trading Alerts and Improvement Suggestions

Teva Pharmaceutical generates negative expected return over the last 30 days
Teva Pharmaceutical has high historical volatility and very poor performance
Teva Pharmaceutical has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company has accumulated 29.16B in total debt with debt to equity ratio (D/E) of 184.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Teva Pharmaceutical has Current Ratio of 0.94 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported revenue of 18.08B. Net Loss for the year was (3.56B) with profit before overhead, payroll, taxes, and interest of 8.3B.

Teva Pharmaceutical current analysts recommendations

Target Median Price26.00
Target Mean Price26.00
Target High Price26.00
Number Of Analyst Opinions1
Target Low Price26.00

Teva Pharmaceutical Returns Distribution Density

Mean Return0.86Value At Risk6.55
Potential Upside2.54Standard Deviation3.11
 Return Density 

Teva Pharmaceutical Greeks

Alpha over DOW
Beta against DOW=0.00
Overall volatility
Information ratio =0.00

Teva Pharmaceutical Volatility Alert

Teva Pharmaceutical Industries Limited exhibits very low volatility with skewness of -1.96 and kurtosis of 6.1. However, we advise investors to further study Teva Pharmaceutical Industries Limited technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Teva Pharmaceutical to competition

Teva Pharmaceutical Fundamental Vs Peers

FundamentalsTeva PharmaceuticalPeer Average
Return On Equity(20.62)% (0.31)%
Return On Asset2.60% (0.14)%
Profit Margin(18.66)% (1.27)%
Operating Margin14.85% (5.51)%
Current Valuation73.03B16.62B
Shares Outstanding1.02B571.82M
Price to Earning(773.90)X28.72X
Price to Book314.91X9.51X
Price to Sales2.39X11.42X
Gross Profit8.3B27.38B
Net Income(3.56B)570.98M
Cash and Equivalents1.97B2.7B
Cash per Share1.81X5.01X
Total Debt29.16B5.32B
Debt to Equity184.30% 48.70%
Current Ratio0.96X2.16X
Book Value Per Share13.50X1.93K
Cash Flow from Operations1.06B971.22M
Earnings Per Share(3.42)X3.12X
Price to Earnings To Growth0.50X4.89X
Number of Employees42.53K18.84K
Market Capitalization43.3B19.03B
Total Asset54.26B29.47B
Retained Earnings14.99B9.33B
Working Capital5.39B1.48B
Current Asset18.4B9.34B
Current Liabilities13.01B7.9B
Z Score0.68.72
Five Year Return2.96%
Last Dividend Paid5.32